Ivergelan (Ivermectin)

Ivergelan (ivermectin) is indicated for parasitic infections caused by nematodes and ectoparasites, helping to eliminate the organisms and reduce disease manifestations.

• Onchocerciasis: reduces microfilarial load and helps prevent ocular and skin disease progression.
• Strongyloidiasis: eradicates intestinal larvae, preventing chronic infection and hyperinfection syndrome.
• Scabies: eliminates the Sarcoptes scabiei mite, relieving itching and skin lesions.
• Lymphatic filariasis: decreases microfilariae in blood, contributing to transmission control.
• Other helminth infections: provides broad‑spectrum activity against various intestinal and tissue‑dwelling worms.

• Ivermectin binds selectively to glutamate‑gated chloride channels found in invertebrate nerve and muscle cells. This binding increases chloride ion permeability, leading to hyperpolarization of the cell membrane, paralysis of the parasite, and ultimately its death. The drug shows minimal affinity for mammalian GABA receptors, which limits central nervous system effects in humans.

Ivergelan may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Mild skin rash: localized erythema or pruritus.
• Nausea: transient feeling of queasiness.
• Diarrhea: loose stools, usually self‑limiting.
• Dizziness: light‑headed sensation, often resolves without intervention.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rapid onset of airway swelling, hypotension, and rash.
• Hepatotoxicity: elevated liver enzymes or jaundice.
• Neurological manifestations: seizures, ataxia, or altered mental status.

Before prescribing Ivergelan, clinicians should consider several safety factors.

• Pregnancy: safety not established; use only if benefits outweigh potential risks.
• Breastfeeding: consult a healthcare provider; ivermectin may be excreted in breast milk.
• Renal impairment: dose adjustment may be required; monitor renal function closely.
• Concomitant CNS depressants: may enhance neurologic effects; observe the patient.
• Drug interactions: review all current medications for potential interactions.
• Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Ivergelan can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid)

• Co‑administration with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase ivermectin plasma concentrations.
• Concurrent use with P‑glycoprotein inhibitors (e.g., verapamil) can raise systemic exposure.
• Combination with other neurotoxic antiparasitics may potentiate neurotoxicity.

Moderate Interactions (Monitor Closely)

• Concurrent use with warfarin may affect anticoagulation; monitor INR regularly.
• Combination with other antiparasitic agents (e.g., albendazole) may increase the risk of adverse effects.
• Use with macrolide antibiotics may modestly increase ivermectin levels; observe for side‑effects.